Axsome Therapeutics is trading 4.1% up now at $230.64, rebounding after recent pullbacks amid strong biotech sector gains and optimism surrounding its CNS pipeline.
- The FDA has accepted the New Drug Application (NDA) for AXS-12 for the treatment of narcolepsy cataplexy, with a target action date of July 15, 2026.
- Investor focus remains on the company’s expanding portfolio, including the successful commercialization of Auvelity and other recent CNS product launches.